GTPase KRas G13D mutant peptide epitope (KRAS G13D)

The Mutant KRAS G13D peptide epitope is a tumor-specific neoantigen resulting from a missense mutation in the KRAS gene, where glycine at position 13 is substituted with aspartic acid (Source 1.3.4). This mutation is a frequent driver in various malignancies, particularly colorectal, pancreatic, and lung cancers, leading to a constitutively active KRAS protein that promotes uncontrolled cell proliferation and survival (Source 1.2.1, 1.3.3). As a neoantigen, the G13D peptide is processed and presented on the surface of cancer cells by Major Histocompatibility Complex (MHC) molecules, making it a precise target for immunotherapy (Source 1.1.3, 1.1.4). Therapeutic strategies targeting this epitope include neoantigen vaccines like mRNA-5671 and ELI-002, which aim to elicit a robust T-cell response against the mutation (Source 1.1.2, 1.2.1). Additionally, adoptive cell therapies, such as T-cell receptor (TCR) engineered T cells, are being developed to specifically recognize the G13D peptide-HLA complex, often restricted by alleles like HLA-A*11:01 (Source 1.4.1, 1.4.2). Notably, the G13D mutation is biochemically distinct from other KRAS mutations, which may influence its sensitivity to certain targeted therapies like the EGFR inhibitor cetuximab (Source 1.3.2, 1.4.3). Targeting this epitope represents a significant advancement in precision oncology, offering a way to selectively eliminate cancer cells while sparing healthy tissue (Source 1.1.5).

Other names

KRAS G13D neoantigenKRAS G13D mutant peptidep.G13D KRASKRAS G13D neoepitopeKirsten rat sarcoma virus oncogene homolog G13D peptide

Induction of T-cell mediated cytotoxicity against cells presenting the mutant peptide on HLA molecules (Source 1.1.1, 1.1.4).